<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486834</url>
  </required_header>
  <id_info>
    <org_study_id>V160-002</org_study_id>
    <secondary_id>2017-004233-86</secondary_id>
    <nct_id>NCT03486834</nct_id>
  </id_info>
  <brief_title>V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV)&#xD;
      vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to&#xD;
      35 years of age. Participants received blinded V160 on Day 1, Month 2, and Month 6 (3-dose&#xD;
      regimen), V160 on Day 1 and Month 6 and placebo at Month 2 (2-dose regimen), or placebo on&#xD;
      Day 1, Month 2, and Month 6, and were followed to approximately Month 24. The primary&#xD;
      hypothesis of the study was that administration of a 3-dose regimen of V160 will reduce the&#xD;
      incidence of primary CMV infection compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">October 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection Starting at 4 Weeks Post Last Dose (V160 3-dose Regimen Group and Placebo Group)</measure>
    <time_frame>4 weeks post last vaccination (Month 7) up to ~Month 24</time_frame>
    <description>Cytomegalovirus infection (CMVi) was defined as the detection of wild-type cytomegalovirus (CMV) (non vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 3-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 3-dose regimen group compared to the placebo group was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Injection-site Adverse Events</measure>
    <time_frame>Up to 5 days after each vaccination</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Systemic AEs</measure>
    <time_frame>Up to 14 days after each vaccination</time_frame>
    <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, joint pain/arthralgia, muscle pain/myalgia, and headache.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vaccine-related Serious Adverse Events</measure>
    <time_frame>Up to 14 days after each vaccination</time_frame>
    <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V160 or placebo, the number of participants with vaccine-related serious adverse events was assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Became Infected With Wild-Type CMV Infection Starting at 4 Weeks Post Last Dose (V160 2-dose Regimen Group and Placebo Group)</measure>
    <time_frame>4 weeks post last vaccination (Month 7) up to ~Month 24</time_frame>
    <description>CMVi is defined as detection of wild-type CMV (non-vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 2-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 2-dose regimen group compared to the placebo group was assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2200</enrollment>
  <condition>Cytomegalovirus (CMV) Infections</condition>
  <arm_group>
    <arm_group_label>V160 3-Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of vaccine V160 (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant [MAPA], 4°C stable formulation) administered by intramuscular (IM) injection on Day 1, Month 2, and Month 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V160 2-Dose Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 doses of vaccine V160 (100 Units/0.5 mL dose with MAPA, 4°C stable formulation) administered IM on Day 1 and Month 6 and a placebo-saline solution at Month 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo (saline solution) by IM injection on Day 1, Month 2, and Month 6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V160</intervention_name>
    <description>V160 was administered as a 0.5 mL (100 Units/0.5 mL dose with Merck aluminum phosphate adjuvant [MAPA], 4°C stable formulation) IM injection.</description>
    <arm_group_label>V160 2-Dose Regimen</arm_group_label>
    <arm_group_label>V160 3-Dose Regimen</arm_group_label>
    <other_name>Human cytomegalovirus vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline solution administered as a 0.5 mL IM injection</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>V160 2-Dose Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy based on medical history and physical examination.&#xD;
&#xD;
          -  Serologically confirmed to be CMV seronegative prior to receiving the first dose of&#xD;
             V160/placebo&#xD;
&#xD;
          -  Have direct exposure to young children (≤5 years of age) at home or occupationally&#xD;
&#xD;
          -  Of childbearing potential&#xD;
&#xD;
          -  Agrees to avoid becoming pregnant during the 6-month treatment period and for at least&#xD;
             4 weeks after the last dose of study drug by either 1) practicing abstinence from&#xD;
             heterosexual activity, or 2) use a highly-effective method of birth control (as&#xD;
             specified in the protocol) during heterosexual activity.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history or current evidence of any condition, therapy, laboratory abnormality or&#xD;
             other circumstance that might expose the participant to risk by participating in the&#xD;
             trial, confound the results of the trial, or interfere with participation for the full&#xD;
             duration of the trial, as assessed by the investigator&#xD;
&#xD;
          -  Has history of allergic reaction or anaphylactic reaction to any vaccine component&#xD;
             that required medical intervention or of any severe allergic reaction to any vaccine&#xD;
             component that required medical intervention.&#xD;
&#xD;
          -  Has a recent (&lt;72 hours) history of febrile illness (temperature ≥100.4°F/38.0°C, oral&#xD;
             equivalent)&#xD;
&#xD;
          -  Is currently immunocompromised or has been diagnosed as having a congenital or&#xD;
             acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma,&#xD;
             leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid&#xD;
             arthritis, inflammatory bowel disease, or other autoimmune condition that requires&#xD;
             immunosuppressive medication.&#xD;
&#xD;
          -  Has a condition in which repeated venipuncture or injections pose more than minimal&#xD;
             risk for the participant.&#xD;
&#xD;
          -  A woman of childbearing potential (WOCBP) who has a positive pregnancy test at&#xD;
             screening or within 24 hours before the first dose of study treatment.&#xD;
&#xD;
          -  Has previously received a CMV vaccine.&#xD;
&#xD;
          -  Had any live virus vaccine administered or scheduled to be administered in the period&#xD;
             from 4 weeks prior to, and 4 weeks following receipt of any dose of trial vaccine.&#xD;
&#xD;
          -  Had any inactivated vaccine administered or scheduled within the period from 14 days&#xD;
             prior to, through 14 days following, any dose of trial vaccine.&#xD;
&#xD;
          -  Had administration of any immune globulin or blood product within 90 days prior to&#xD;
             injection with V160/placebo or scheduled within 30 days thereafter.&#xD;
&#xD;
          -  Received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of&#xD;
             prednisone or ≥20 mg/d for persons weighing &gt;10 kg) for ≥14 consecutive days and has&#xD;
             not completed treatment at least 30 days prior to trial entry.&#xD;
&#xD;
          -  Received systemic corticosteroids exceeding physiologic replacement doses (≈5 mg/d&#xD;
             prednisone equivalent) within 14 days prior to the first vaccination (participants&#xD;
             using inhaled, nasal, or topical steroids are considered eligible for the trial).&#xD;
&#xD;
          -  Received any anti-viral agent with proven or potential activity against CMV two weeks&#xD;
             prior to vaccination or is likely to receive such an agent within 2 weeks after&#xD;
             vaccination.&#xD;
&#xD;
          -  Receiving or has received in the year prior to enrollment immunosuppressive therapies&#xD;
             or other therapies used for solid organ/cell transplant, radiation therapy,&#xD;
             immunosuppressive/cytotoxic immunotherapy, chemotherapy and other immunosuppressive&#xD;
             therapies known to interfere with the immune response. Topical tacrolimus is allowed&#xD;
             provided that it is not used within 2 weeks prior to, or 2 weeks following a V160&#xD;
             dose.&#xD;
&#xD;
          -  Participated in another clinical trial in the past 4 weeks, or plans to participate in&#xD;
             a treatment-based trial or a trial in which an invasive procedure is to be performed&#xD;
             while enrolled in this trial.&#xD;
&#xD;
          -  Plans donation of eggs at any time from signing the informed consent through 1 month&#xD;
             after receiving the last dose of the trial V160/placebo.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics ( Site 0025)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Achieve Clinical Research, LLC ( Site 0055)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus US Phoenix Southeast ( Site 0057)</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation ( Site 0026)</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Research of Inland, Inc. ( Site 0042)</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Foundation ( Site 0286)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bayview Research Group, LLC ( Site 0012)</name>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc ( Site 0009)</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emerson Clinical Research Institute ( Site 0297)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of South Florida ( Site 0047)</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indago Research &amp; Health Center, Inc ( Site 0007)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NF Research Center LLC ( Site 0013)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Quality Research Inc. ( Site 0031)</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Care Partners Clinical Research, LLC ( Site 0002)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L&amp;C Professional Medical Research Institute ( Site 0021)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Institute ( Site 0296)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kendall South Medical Center, Inc ( Site 0008)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33185</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Age Medical Research Corporation ( Site 0018)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Associates of Orlando, LLC ( Site 0032)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute ( Site 0298)</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC ( Site 0044)</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC ( Site 0023)</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC ( Site 0019)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ACC Pediatric Research ( Site 0022)</name>
      <address>
        <city>Haughton</city>
        <state>Louisiana</state>
        <zip>71037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Medicine ( Site 0041)</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Michaels Med Center ( Site 0285)</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials ( Site 0052)</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Hudson Medical Research ( Site 0294)</name>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <zip>12553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Women's Research and Wellness Center ( Site 0035)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh, LLC ( Site 0048)</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington ( Site 0006)</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center ( Site 0003)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senders Pediatrics ( Site 0060)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rapid Medical Research, Inc. ( Site 0038)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynn Health Science Institute ( Site 0287)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Pediatric Research ( Site 0010)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parkside Pediatric ( Site 0288)</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center ( Site 0053)</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Research ( Site 0289)</name>
      <address>
        <city>Summerville</city>
        <state>South Carolina</state>
        <zip>29485</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research, Inc. ( Site 0036)</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Bend Clinical Research ( Site 0299)</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78413</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research - Dallas ( Site 0045)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Medical Branch at Galveston ( Site 0049)</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-1115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC ( Site 0293)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management, LLC ( Site 0028)</name>
      <address>
        <city>Pasadena</city>
        <state>Texas</state>
        <zip>77504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostics Research Group ( Site 0001)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Research ( Site 0058)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crossroads Clinical Research LLC ( Site 0283)</name>
      <address>
        <city>Victoria</city>
        <state>Texas</state>
        <zip>77901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Research of Hampton Roads, Inc. ( Site 0014)</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater ( Site 0056)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>York Clinical Research, LLC ( Site 0033)</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research-Richmond, Inc. ( Site 0051)</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multicare / Rockwood Clinic ( Site 0034)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research Group ( Site 0050)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Pty Ltd - Blacktown Clinic ( Site 0247)</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paratus Clinical Kanwal - Trial Clinic ( Site 0243)</name>
      <address>
        <city>Kanwal</city>
        <state>New South Wales</state>
        <zip>2259</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Practice ( Site 0241)</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast Clinical Trials Centre ( Site 0244)</name>
      <address>
        <city>Morayfield</city>
        <state>Queensland</state>
        <zip>4506</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of the Sunshine Coast Clinical Trials Centre ( Site 0245)</name>
      <address>
        <city>Sippy Downs</city>
        <state>Queensland</state>
        <zip>4556</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vaccine Evaluation Center ( Site 0264)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PrimeHealth Clinical Research ( Site 0070)</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique OVO ( Site 0067)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4P 2S4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre - Vaccine Study Centre ( Site 0064)</name>
      <address>
        <city>Pierrefonds</city>
        <state>Quebec</state>
        <zip>H9H 4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Sherbrooke Inc. ( Site 0066)</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1L 0H8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Victoriaville Inc. ( Site 0068)</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUQ - Unite de Recherche en Sante Publique ( Site 0065)</name>
      <address>
        <city>Quebec</city>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diex Recherche Quebec Inc ( Site 0069)</name>
      <address>
        <city>Quebec</city>
        <zip>G1N 4V3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Espoon rokotetutkimusklinikka ( Site 0186)</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Etela-Helsingin Rokotetutkimusklinikka ( Site 0188)</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ita-Helsingin Rokotetutkimuskeskus ( Site 0184)</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jarvenpaan rokotetutkimuskeskus ( Site 0185)</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Kokkolan rokotetutkimusklinikka ( Site 0190)</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Oulun rokotetutkimusklinikka ( Site 0187)</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pori Vaccine Research Center ( Site 0182)</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seinajoki Vaccine Research Center ( Site 0189)</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampereen yliopisto Rokotetutkimuskeskus ( Site 0181)</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku Vaccine Research Center ( Site 0183)</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center - Health Care Campus ( Site 0219)</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Kerem Medical Center ( Site 0216)</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir MC ( Site 0213)</name>
      <address>
        <city>Kfar Saba</city>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Hospital ( Site 0212)</name>
      <address>
        <city>Nahariya</city>
        <zip>2222214</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center ( Site 0218)</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakhnin west neighbourhood ( Site 0211)</name>
      <address>
        <city>Sakhnin</city>
        <zip>3081000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center ( Site 0217)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maccabi Healthcare Services ( Site 0220)</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6789140</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central City Hospital 7 ( Site 0237)</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limited Liability Company Medical Centre Aibolit ( Site 0229)</name>
      <address>
        <city>Kazan</city>
        <zip>420073</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LLC Scientific Research Medical Complex Your Health. ( Site 0230)</name>
      <address>
        <city>Kazan</city>
        <zip>420097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital 13 of Moscow ( Site 0232)</name>
      <address>
        <city>Moscow</city>
        <zip>115280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antenatal clinic #22 ( Site 0225)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siberian State Medical University ( Site 0231)</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona ( Site 0155)</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre ( Site 0152)</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz ( Site 0157)</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago ( Site 0151)</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <results_first_submitted>October 1, 2021</results_first_submitted>
  <results_first_submitted_qc>October 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 10, 2021</results_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prevention of cytomegalovirus infection (CMVi)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/34/NCT03486834/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of approximately 2100 participants were planned to be enrolled with 2200 participants actually randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>V160 3-Dose Regimen</title>
          <description>Participants received V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="P2">
          <title>V160 2-Dose Regimen</title>
          <description>Participants received V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants received placebo by IM injection on Day 1, Month 2, and Month 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="733"/>
                <participants group_id="P2" count="733"/>
                <participants group_id="P3" count="734"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment 1</title>
              <participants_list>
                <participants group_id="P1" count="729"/>
                <participants group_id="P2" count="729"/>
                <participants group_id="P3" count="733"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment 2</title>
              <participants_list>
                <participants group_id="P1" count="680"/>
                <participants group_id="P2" count="680"/>
                <participants group_id="P3" count="679"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treatment 3</title>
              <participants_list>
                <participants group_id="P1" count="614"/>
                <participants group_id="P2" count="631"/>
                <participants group_id="P3" count="622"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="614"/>
                <participants group_id="P2" count="631"/>
                <participants group_id="P3" count="622"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="112"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Deviation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Parent/Guardian</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>V160 3-Dose Regimen</title>
          <description>Participants received V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="B2">
          <title>V160 2-Dose Regimen</title>
          <description>Participants received V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received placebo by IM injection on Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="733"/>
            <count group_id="B2" value="733"/>
            <count group_id="B3" value="734"/>
            <count group_id="B4" value="2200"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.0" spread="5.0"/>
                    <measurement group_id="B2" value="26.1" spread="4.9"/>
                    <measurement group_id="B3" value="25.9" spread="4.9"/>
                    <measurement group_id="B4" value="26.0" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="733"/>
                    <measurement group_id="B2" value="733"/>
                    <measurement group_id="B3" value="734"/>
                    <measurement group_id="B4" value="2200"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="144"/>
                    <measurement group_id="B2" value="145"/>
                    <measurement group_id="B3" value="143"/>
                    <measurement group_id="B4" value="432"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="588"/>
                    <measurement group_id="B2" value="585"/>
                    <measurement group_id="B3" value="587"/>
                    <measurement group_id="B4" value="1760"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="139"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="657"/>
                    <measurement group_id="B2" value="652"/>
                    <measurement group_id="B3" value="665"/>
                    <measurement group_id="B4" value="1974"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection Starting at 4 Weeks Post Last Dose (V160 3-dose Regimen Group and Placebo Group)</title>
        <description>Cytomegalovirus infection (CMVi) was defined as the detection of wild-type cytomegalovirus (CMV) (non vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 3-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 3-dose regimen group compared to the placebo group was assessed.</description>
        <time_frame>4 weeks post last vaccination (Month 7) up to ~Month 24</time_frame>
        <population>The analysis population included participants who were CMV seronegative at Day 1 and CMV negative by polymerase chain reaction (PCR) for nonvaccine strain virus from post Day 1 through Month 7, had received all 3 injections/vaccinations within the vaccination visit window, and did not have any deviations from protocol deemed to potentially interfere with the evaluation of efficacy or immune response to injection of V160.</population>
        <group_list>
          <group group_id="O1">
            <title>V160 3-Dose Regimen</title>
            <description>Participants received V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo by IM injection on Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Became Infected With Wild-Type Cytomegalovirus Infection Starting at 4 Weeks Post Last Dose (V160 3-dose Regimen Group and Placebo Group)</title>
          <description>Cytomegalovirus infection (CMVi) was defined as the detection of wild-type cytomegalovirus (CMV) (non vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 3-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 3-dose regimen group compared to the placebo group was assessed.</description>
          <population>The analysis population included participants who were CMV seronegative at Day 1 and CMV negative by polymerase chain reaction (PCR) for nonvaccine strain virus from post Day 1 through Month 7, had received all 3 injections/vaccinations within the vaccination visit window, and did not have any deviations from protocol deemed to potentially interfere with the evaluation of efficacy or immune response to injection of V160.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="556"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The incidence rate per 100 person years (100 x number of CMVi cases/total person-years to CMVi or end of follow-up) is presented along with 95% confidence interval (CI).</non_inferiority_desc>
            <param_type>Incidence Rate Estimate</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.6</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The incidence rate per 100 person years (100 x number of CMVi cases/total person-years to CMVi or end of follow-up) is presented along with 95% CI.</non_inferiority_desc>
            <param_type>Incidence Rate Estimate</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The statistical criterion for success requires the lower limit of the 95% CI of vaccine efficacy (VE) to be greater than 0%.</non_inferiority_desc>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>42.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.5</ci_lower_limit>
            <ci_upper_limit>71.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Injection-site Adverse Events</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and pain.</description>
        <time_frame>Up to 5 days after each vaccination</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 injection of V160 or placebo, had safety follow-up data, and had been assigned to the treatment arm corresponding to the actual clinical material received.</population>
        <group_list>
          <group group_id="O1">
            <title>V160 3-Dose Regimen</title>
            <description>Participants received V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>V160 2-Dose Regimen</title>
            <description>Participants received V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo by IM injection on Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection-site Adverse Events</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited injection-site AEs was assessed. The solicited injection-site AEs assessed were redness/erythema, swelling, and pain.</description>
          <population>The analysis population included all randomized participants who received at least 1 injection of V160 or placebo, had safety follow-up data, and had been assigned to the treatment arm corresponding to the actual clinical material received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="728"/>
                <count group_id="O2" value="729"/>
                <count group_id="O3" value="732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="683"/>
                    <measurement group_id="O2" value="668"/>
                    <measurement group_id="O3" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>59.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>55.8</ci_lower_limit>
            <ci_upper_limit>63.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>57.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.5</ci_lower_limit>
            <ci_upper_limit>61.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Systemic AEs</title>
        <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, joint pain/arthralgia, muscle pain/myalgia, and headache.</description>
        <time_frame>Up to 14 days after each vaccination</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 injection of V160 or placebo, had safety follow-up data, and had been assigned to the treatment arm corresponding to the actual clinical material received.</population>
        <group_list>
          <group group_id="O1">
            <title>V160 3-Dose Regimen</title>
            <description>Participants received V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>V160 2-Dose Regimen</title>
            <description>Participants received V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo by IM injection on Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic AEs</title>
          <description>An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study treatment. Following vaccination with V160 or placebo, the number of participants with solicited systemic AEs was assessed. The solicited systemic AEs assessed were fatigue, joint pain/arthralgia, muscle pain/myalgia, and headache.</description>
          <population>The analysis population included all randomized participants who received at least 1 injection of V160 or placebo, had safety follow-up data, and had been assigned to the treatment arm corresponding to the actual clinical material received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="728"/>
                <count group_id="O2" value="729"/>
                <count group_id="O3" value="732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="621"/>
                    <measurement group_id="O2" value="633"/>
                    <measurement group_id="O3" value="508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>15.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>11.7</ci_lower_limit>
            <ci_upper_limit>20.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>17.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>13.3</ci_lower_limit>
            <ci_upper_limit>21.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vaccine-related Serious Adverse Events</title>
        <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V160 or placebo, the number of participants with vaccine-related serious adverse events was assessed.</description>
        <time_frame>Up to 14 days after each vaccination</time_frame>
        <population>The analysis population included all randomized participants who received at least 1 injection of V160 or placebo, had safety follow-up data, and had been assigned to the treatment arm corresponding to the actual clinical material received.</population>
        <group_list>
          <group group_id="O1">
            <title>V160 3-Dose Regimen</title>
            <description>Participants received V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.</description>
          </group>
          <group group_id="O2">
            <title>V160 2-Dose Regimen</title>
            <description>Participants received V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received placebo by IM injection on Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Vaccine-related Serious Adverse Events</title>
          <description>A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Relatedness of an SAE to the study vaccine was determined by the investigator. Following vaccination with V160 or placebo, the number of participants with vaccine-related serious adverse events was assessed.</description>
          <population>The analysis population included all randomized participants who received at least 1 injection of V160 or placebo, had safety follow-up data, and had been assigned to the treatment arm corresponding to the actual clinical material received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="728"/>
                <count group_id="O2" value="729"/>
                <count group_id="O3" value="732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Difference in Percent</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Became Infected With Wild-Type CMV Infection Starting at 4 Weeks Post Last Dose (V160 2-dose Regimen Group and Placebo Group)</title>
        <description>CMVi is defined as detection of wild-type CMV (non-vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 2-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 2-dose regimen group compared to the placebo group was assessed.</description>
        <time_frame>4 weeks post last vaccination (Month 7) up to ~Month 24</time_frame>
        <population>The analysis population included participants who were CMV seronegative at Day 1 and CMV negative by polymerase chain reaction (PCR) for nonvaccine strain virus from post Day 1 through Month 7, had received all 2 injections/vaccinations within the vaccination visit window, and did not have any deviations from protocol deemed to potentially interfere with the evaluation of efficacy or immune response to injection of V160.</population>
        <group_list>
          <group group_id="O1">
            <title>V160 2-Dose Regimen</title>
            <description>Participants received V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo by IM injection on Day 1, Month 2, and Month 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Became Infected With Wild-Type CMV Infection Starting at 4 Weeks Post Last Dose (V160 2-dose Regimen Group and Placebo Group)</title>
          <description>CMVi is defined as detection of wild-type CMV (non-vaccine type) by polymerase chain reaction in a single saliva or urine sample in a previously CMV-uninfected participant. CMVi cases in the 2-dose regimen and placebo groups were reported and incidence rate (per 100 person-years) calculated based on follow-up time starting at 4 weeks post last dose (Month 7) through approximately Month 24 (or time point to reach required cases for assessment). The percent reduction in CMVi incidence rate in the 2-dose regimen group compared to the placebo group was assessed.</description>
          <population>The analysis population included participants who were CMV seronegative at Day 1 and CMV negative by polymerase chain reaction (PCR) for nonvaccine strain virus from post Day 1 through Month 7, had received all 2 injections/vaccinations within the vaccination visit window, and did not have any deviations from protocol deemed to potentially interfere with the evaluation of efficacy or immune response to injection of V160.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="546"/>
                <count group_id="O2" value="543"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The incidence rate per 100 person years (100 x number of CMVi cases/total person-years to CMVi or end of follow-up) is presented along with 95% CI.</non_inferiority_desc>
            <param_type>Incidence Rate Estimate</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.6</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The incidence rate per 100 person years (100 x number of CMVi cases/total person-years to CMVi or end of follow-up) is presented along with 95% CI.</non_inferiority_desc>
            <param_type>Incidence Rate Estimate</param_type>
            <param_value>5.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.3</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The statistical criterion for success requires the lower limit of the 95% CI of vaccine efficacy (VE) to be greater than 0%.</non_inferiority_desc>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>-32.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-135.0</ci_lower_limit>
            <ci_upper_limit>25.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-cause mortality and serious adverse events: Up to ~Month 24; Non-serious adverse events: Up to 14 days following any vaccination.</time_frame>
      <desc>The analysis population for the serious and non-serious adverse events included all randomized participants who received at least 1 injection of V160 or placebo, had safety follow-up data, and had been assigned to the treatment arm corresponding to the actual clinical material received. The all-cause mortality analysis population included all randomized participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>V160 3-Dose Group</title>
          <description>Participants received V160 vaccination by intramuscular (IM) injection on Day 1, Month 2, and Month 6.</description>
        </group>
        <group group_id="E2">
          <title>V160 2-Dose Group</title>
          <description>Participants received V160 vaccination by IM injection on Day 1 and Month 6 and placebo at Month 2.</description>
        </group>
        <group group_id="E3">
          <title>Placebo Group</title>
          <description>Participants received placebo by IM injection on Day 1, Month 2, and Month 6.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="733"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="734"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="728"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="729"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Pelvic bone injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Procedural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Traumatic arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Enchondromatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Idiopathic intracranial hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="728"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="729"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Anembryonic gestation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Eclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Intermenstrual bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="729"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="728"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="729"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="697" subjects_at_risk="728"/>
                <counts group_id="E2" subjects_affected="700" subjects_at_risk="729"/>
                <counts group_id="E3" subjects_affected="557" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="50" subjects_affected="45" subjects_at_risk="728"/>
                <counts group_id="E2" events="68" subjects_affected="55" subjects_at_risk="729"/>
                <counts group_id="E3" events="54" subjects_affected="46" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1128" subjects_affected="457" subjects_at_risk="728"/>
                <counts group_id="E2" events="1077" subjects_affected="461" subjects_at_risk="729"/>
                <counts group_id="E3" events="843" subjects_affected="357" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="400" subjects_affected="254" subjects_at_risk="728"/>
                <counts group_id="E2" events="273" subjects_affected="208" subjects_at_risk="729"/>
                <counts group_id="E3" events="39" subjects_affected="30" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1943" subjects_affected="680" subjects_at_risk="728"/>
                <counts group_id="E2" events="1524" subjects_affected="664" subjects_at_risk="729"/>
                <counts group_id="E3" events="374" subjects_affected="239" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="54" subjects_affected="44" subjects_at_risk="728"/>
                <counts group_id="E2" events="34" subjects_affected="26" subjects_at_risk="729"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="404" subjects_affected="248" subjects_at_risk="728"/>
                <counts group_id="E2" events="311" subjects_affected="233" subjects_at_risk="729"/>
                <counts group_id="E3" events="26" subjects_affected="21" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="93" subjects_affected="75" subjects_at_risk="728"/>
                <counts group_id="E2" events="112" subjects_affected="90" subjects_at_risk="729"/>
                <counts group_id="E3" events="42" subjects_affected="27" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="59" subjects_affected="53" subjects_at_risk="728"/>
                <counts group_id="E2" events="56" subjects_affected="53" subjects_at_risk="729"/>
                <counts group_id="E3" events="40" subjects_affected="37" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="226" subjects_affected="162" subjects_at_risk="728"/>
                <counts group_id="E2" events="249" subjects_affected="162" subjects_at_risk="729"/>
                <counts group_id="E3" events="121" subjects_affected="76" subjects_at_risk="732"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="996" subjects_affected="455" subjects_at_risk="728"/>
                <counts group_id="E2" events="818" subjects_affected="424" subjects_at_risk="729"/>
                <counts group_id="E3" events="336" subjects_affected="200" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="988" subjects_affected="434" subjects_at_risk="728"/>
                <counts group_id="E2" events="976" subjects_affected="450" subjects_at_risk="729"/>
                <counts group_id="E3" events="795" subjects_affected="368" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="81" subjects_affected="62" subjects_at_risk="728"/>
                <counts group_id="E2" events="80" subjects_affected="65" subjects_at_risk="729"/>
                <counts group_id="E3" events="80" subjects_affected="69" subjects_at_risk="732"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If publication activity is not directed by the sponsor, the investigator agrees to submit all manuscripts or abstracts to the sponsor before submission. This allows the sponsor to protect proprietary information and to provide comments. Authorship will be determined by mutual agreement and in line with International Committee of Medical Journal Editors authorship requirements.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

